BioCentury
ARTICLE | Clinical News

biOasis preclinical data

September 10, 2012 7:00 AM UTC

In a mouse xenograft model of aggressive human breast carcinoma, twice-weekly subcutaneous BT2111 completely halted tumor growth vs. a 400% increase in tumor size for placebo (p=0.0058). BT2111 was al...